Literature DB >> 34292776

Risk of Late-Onset Breast Cancer in Genetically Predisposed Women.

Nicholas J Boddicker1, Chunling Hu1, Jeffrey N Weitzel2, Peter Kraft3, Katherine L Nathanson4,5, David E Goldgar6, Jie Na1, Hongyan Huang3, Rohan D Gnanaolivu1, Nicole Larson1, Amal Yussuf7, Song Yao8, Celine M Vachon1, Amy Trentham-Dietz9, Lauren Teras10, Jack A Taylor11, Christopher E Scott1, Dale P Sandler11, Tina Pesaran7, Alpa V Patel10, Julie R Palmer12, Irene M Ong9, Janet E Olson1, Katie O'Brien11, Susan Neuhausen2, Elena Martinez2, Huiyan Ma2, Sara Lindstrom13, Loic Le Marchand14, Charles Kooperberg15, Rachid Karam7, David J Hunter16, James M Hodge10, Christopher Haiman17, Mia M Gaudet10, Chi Gao3, Holly LaDuca7, James V Lacey2, Jill S Dolinsky7, Elizabeth Chao7, Brian D Carter10, Elizabeth S Burnside9, Kimberly A Bertrand12, Leslie Bernstein2, Paul W Auer18, Christine Ambrosone8, Siddhartha Yadav1, Steven N Hart1, Eric C Polley1, Susan M Domchek4,5, Fergus J Couch1.   

Abstract

PURPOSE: The prevalence of germline pathogenic variants (PVs) in established breast cancer predisposition genes in women in the general population over age 65 years is not well-defined. However, testing guidelines suggest that women diagnosed with breast cancer over age 65 years might have < 2.5% likelihood of a PV in a high-penetrance gene. This study aimed to establish the frequency of PVs and remaining risks of breast cancer for each gene in women over age 65 years.
METHODS: A total of 26,707 women over age 65 years from population-based studies (51.5% with breast cancer and 48.5% unaffected) were tested for PVs in germline predisposition gene. Frequencies of PVs and associations between PVs in each gene and breast cancer were assessed, and remaining lifetime breast cancer risks were estimated for non-Hispanic White women with PVs.
RESULTS: The frequency of PVs in predisposition genes was 3.18% for women with breast cancer and 1.48% for unaffected women over age 65 years. PVs in BRCA1, BRCA2, and PALB2 were found in 3.42% of women diagnosed with estrogen receptor (ER)-negative, 1.0% with ER-positive, and 3.01% with triple-negative breast cancer. Frequencies of PVs were lower among women with no first-degree relatives with breast cancer. PVs in CHEK2, PALB2, BRCA2, and BRCA1 were associated with increased risks (odds ratio = 2.9-4.0) of breast cancer. Remaining lifetime risks of breast cancer were ≥ 15% for those with PVs in BRCA1, BRCA2, and PALB2.
CONCLUSION: This study suggests that all women diagnosed with triple-negative breast cancer or ER-negative breast cancer should receive genetic testing and that women over age 65 years with BRCA1 and BRCA2 PVs and perhaps with PALB2 and CHEK2 PVs should be considered for magnetic resonance imaging screening.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34292776      PMCID: PMC8547938          DOI: 10.1200/JCO.21.00531

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   50.717


  35 in total

1.  Association between the Lynch syndrome gene MSH2 and breast cancer susceptibility in a Canadian familial cancer registry.

Authors:  Mira Goldberg; Kathleen Bell; Melyssa Aronson; Kara Semotiuk; Greg Pond; Steven Gallinger; Kevin Zbuk
Journal:  J Med Genet       Date:  2017-08-04       Impact factor: 6.318

2.  Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.

Authors:  Susan M Domchek; Tara M Friebel; Christian F Singer; D Gareth Evans; Henry T Lynch; Claudine Isaacs; Judy E Garber; Susan L Neuhausen; Ellen Matloff; Rosalind Eeles; Gabriella Pichert; Laura Van t'veer; Nadine Tung; Jeffrey N Weitzel; Fergus J Couch; Wendy S Rubinstein; Patricia A Ganz; Mary B Daly; Olufunmilayo I Olopade; Gail Tomlinson; Joellen Schildkraut; Joanne L Blum; Timothy R Rebbeck
Journal:  JAMA       Date:  2010-09-01       Impact factor: 56.272

3.  NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020.

Authors:  Mary B Daly; Robert Pilarski; Matthew B Yurgelun; Michael P Berry; Saundra S Buys; Patricia Dickson; Susan M Domchek; Ahmed Elkhanany; Susan Friedman; Judy E Garber; Michael Goggins; Mollie L Hutton; Seema Khan; Catherine Klein; Wendy Kohlmann; Allison W Kurian; Christine Laronga; Jennifer K Litton; Julie S Mak; Carolyn S Menendez; Sofia D Merajver; Barbara S Norquist; Kenneth Offit; Tuya Pal; Holly J Pederson; Gwen Reiser; Kristen Mahoney Shannon; Kala Visvanathan; Jeffrey N Weitzel; Myra J Wick; Kari B Wisinski; Mary A Dwyer; Susan D Darlow
Journal:  J Natl Compr Canc Netw       Date:  2020-04       Impact factor: 11.908

4.  A Recurrent ERCC3 Truncating Mutation Confers Moderate Risk for Breast Cancer.

Authors:  Joseph Vijai; Sabine Topka; Danylo Villano; Vignesh Ravichandran; Kara N Maxwell; Ann Maria; Tinu Thomas; Pragna Gaddam; Anne Lincoln; Sarah Kazzaz; Brandon Wenz; Shai Carmi; Kasmintan A Schrader; Steven N Hart; Steve M Lipkin; Susan L Neuhausen; Michael F Walsh; Liying Zhang; Flavio Lejbkowicz; Hedy Rennert; Zsofia K Stadler; Mark Robson; Jeffrey N Weitzel; Susan Domchek; Mark J Daly; Fergus J Couch; Katherine L Nathanson; Larry Norton; Gad Rennert; Kenneth Offit
Journal:  Cancer Discov       Date:  2016-09-21       Impact factor: 39.397

5.  Rare mutations in RINT1 predispose carriers to breast and Lynch syndrome-spectrum cancers.

Authors:  Daniel J Park; Kayoko Tao; Florence Le Calvez-Kelm; Tu Nguyen-Dumont; Nivonirina Robinot; Fleur Hammet; Fabrice Odefrey; Helen Tsimiklis; Zhi L Teo; Louise B Thingholm; Erin L Young; Catherine Voegele; Andrew Lonie; Bernard J Pope; Terrell C Roane; Russell Bell; Hao Hu; Chad D Huff; Jonathan Ellis; Jun Li; Igor V Makunin; Esther M John; Irene L Andrulis; Mary B Terry; Mary Daly; Saundra S Buys; Carrie Snyder; Henry T Lynch; Peter Devilee; Graham G Giles; John L Hopper; Bing-Jian Feng; Fabienne Lesueur; Sean V Tavtigian; Melissa C Southey; David E Goldgar
Journal:  Cancer Discov       Date:  2014-05-02       Impact factor: 39.397

6.  Exome sequencing identifies FANCM as a susceptibility gene for triple-negative breast cancer.

Authors:  Johanna I Kiiski; Liisa M Pelttari; Sofia Khan; Edda S Freysteinsdottir; Inga Reynisdottir; Steven N Hart; Hermela Shimelis; Sara Vilske; Anne Kallioniemi; Johanna Schleutker; Arto Leminen; Ralf Bützow; Carl Blomqvist; Rosa B Barkardottir; Fergus J Couch; Kristiina Aittomäki; Heli Nevanlinna
Journal:  Proc Natl Acad Sci U S A       Date:  2014-10-06       Impact factor: 11.205

7.  Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients.

Authors:  Holly LaDuca; A J Stuenkel; Jill S Dolinsky; Steven Keiles; Stephany Tandy; Tina Pesaran; Elaine Chen; Chia-Ling Gau; Erika Palmaer; Kamelia Shoaepour; Divya Shah; Virginia Speare; Stephanie Gandomi; Elizabeth Chao
Journal:  Genet Med       Date:  2014-04-24       Impact factor: 8.822

8.  A clinical guide to hereditary cancer panel testing: evaluation of gene-specific cancer associations and sensitivity of genetic testing criteria in a cohort of 165,000 high-risk patients.

Authors:  Holly LaDuca; Eric C Polley; Amal Yussuf; Lily Hoang; Stephanie Gutierrez; Steven N Hart; Siddhartha Yadav; Chunling Hu; Jie Na; David E Goldgar; Kelly Fulk; Laura Panos Smith; Carolyn Horton; Jessica Profato; Tina Pesaran; Chia-Ling Gau; Melissa Pronold; Brigette Tippin Davis; Elizabeth C Chao; Fergus J Couch; Jill S Dolinsky
Journal:  Genet Med       Date:  2019-08-13       Impact factor: 8.822

9.  Analysis of PALB2/FANCN-associated breast cancer families.

Authors:  Marc Tischkowitz; Bing Xia; Nelly Sabbaghian; Jorge S Reis-Filho; Nancy Hamel; Guilan Li; Erik H van Beers; Lili Li; Tayma Khalil; Louise A Quenneville; Atilla Omeroglu; Aletta Poll; Pierre Lepage; Nora Wong; Petra M Nederlof; Alan Ashworth; Patricia N Tonin; Steven A Narod; David M Livingston; William D Foulkes
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-09       Impact factor: 11.205

10.  Breast-cancer risk in families with mutations in PALB2.

Authors:  Antonis C Antoniou; Silvia Casadei; Tuomas Heikkinen; Daniel Barrowdale; Katri Pylkäs; Jonathan Roberts; Andrew Lee; Deepak Subramanian; Kim De Leeneer; Florentia Fostira; Eva Tomiak; Susan L Neuhausen; Zhi L Teo; Sofia Khan; Kristiina Aittomäki; Jukka S Moilanen; Clare Turnbull; Sheila Seal; Arto Mannermaa; Anne Kallioniemi; Geoffrey J Lindeman; Saundra S Buys; Irene L Andrulis; Paolo Radice; Carlo Tondini; Siranoush Manoukian; Amanda E Toland; Penelope Miron; Jeffrey N Weitzel; Susan M Domchek; Bruce Poppe; Kathleen B M Claes; Drakoulis Yannoukakos; Patrick Concannon; Jonine L Bernstein; Paul A James; Douglas F Easton; David E Goldgar; John L Hopper; Nazneen Rahman; Paolo Peterlongo; Heli Nevanlinna; Mary-Claire King; Fergus J Couch; Melissa C Southey; Robert Winqvist; William D Foulkes; Marc Tischkowitz
Journal:  N Engl J Med       Date:  2014-08-07       Impact factor: 91.245

View more
  3 in total

1.  Race and Site of Care Impact Treatment Delays in Older Women with Non-Metastatic Breast Cancer.

Authors:  Julia H Song; Olga Kantor; Elizabeth A Mittendorf; Tari A King; Christina A Minami
Journal:  Ann Surg Oncol       Date:  2022-03-30       Impact factor: 4.339

2.  Systematic pan-cancer analysis on the expression and role of regulator of chromatin condensation 1/small nucleolar RNA host gene 3/small nucleolar RNA host gene 12.

Authors:  Kai Hu; Huomei Yu; Shiyan Liu; Deyu Liao; Yan Zhang
Journal:  Front Mol Biosci       Date:  2022-09-06

Review 3.  Controversies and Open Questions in Management of Cancer-Free Carriers of Germline Pathogenic Variants in BRCA1/BRCA2.

Authors:  Rinat Bernstein-Molho; Eitan Friedman; Ella Evron
Journal:  Cancers (Basel)       Date:  2022-09-22       Impact factor: 6.575

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.